Immune retraining: could CAR-Treg cells tame autoimmune disease?

NCT ID NCT07502859

Not yet recruiting Disease control Sponsor: Beijing Boren Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests a new treatment called BEN301, which uses specially engineered immune cells (CAR-Tregs) to calm overactive immune responses in people with autoimmune diseases like scleroderma, rheumatoid arthritis, lupus, and inflammatory muscle disease. The trial will enroll 24 adults to check if the treatment is safe and tolerable. The goal is to see if these cells can reduce disease activity without causing serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BEN301 injection (CAR-Treg cells)
What this could lead to: If successful, this could point toward a new way to control autoimmune diseases by retraining the immune system to stop attacking the body.
What could go wrong: This is a very early, small trial (24 people) focused on safety. The treatment may not work or could cause unexpected side effects. It is not a cure and long-term effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy dermatomyositis polymyositis rheumatoid arthritis Sjogren syndrome systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SSC RA SS IIM

Contacts and locations

Locations

Boren Hospital, Beijing.

Beijing, Beijing Municipality, 100070, China
Shanghai Jiaotong University School of Medicine, Renji Hospital

Shanghai, Shanghai Municipality, 200127, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.